secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aurinia Pharmaceuticals Inc. (AUPH)
CIK:        0001600620
Form:       8-K
Filed at:   2023-05-04T23:59:59+00:00
Accession:  0001600620-23-000010
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aurinia Q1 net revenue $34.4M (+59% YoY); raises 2023 revenue guidance to $135-155M
--------------------------------------------------------------------------------

- Net product revenue $34.3M, up from $21.5M in Q1 2022; net loss $26.2M ($0.18/share) vs $37.6M loss a year ago.
- Raised FY 2023 LUPKYNIS net product revenue guidance to $135-155M, from prior $120-140M.
- 1,731 patients on LUPKYNIS therapy at March 31, 2023, up from 1,071 a year earlier; 466 PSFs added in Q1.
- New method-of-use patent issued; NICE positive recommendation for LUPKYNIS in UK; Swiss regulatory approval received.
- Cash and short-term investments $361.5M at quarter end vs $389.4M at Dec 31, 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1600620/000160062023000010/0001600620-23-000010-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1600620/000160062023000010/auph-20230504.htm
  HTML page:      https://secwatch.observer/filing/0001600620-23-000010

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer